PE20190972A1 - Combinacion de agonistas de fxr - Google Patents
Combinacion de agonistas de fxrInfo
- Publication number
- PE20190972A1 PE20190972A1 PE2019000497A PE2019000497A PE20190972A1 PE 20190972 A1 PE20190972 A1 PE 20190972A1 PE 2019000497 A PE2019000497 A PE 2019000497A PE 2019000497 A PE2019000497 A PE 2019000497A PE 20190972 A1 PE20190972 A1 PE 20190972A1
- Authority
- PE
- Peru
- Prior art keywords
- fxr agonist
- dose
- acid
- agonist combination
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMBINACION FARMACEUTICA QUE CONTIENE A) UN AGONISTA DE FXR NO DERIVADO DE ACIDO BILIAR TAL COMO EL ACIDO 2-[3-({5-CICLOPROPIL-3-[2-(TRIFLUOROMETOXI)FENIL]-1,2-OXAZOL-4-IL}METOXI)-8-AZABICICLO[3.2.1]OCTAN-8-IL]-4-FLUORO-1,3-BENZOTIAZOL-6-CARBOXILICO EN UNA DOSIS DE 3 µg A 100 µg; Y B) UNO O VARIOS AGENTES TERAPEUTICOS ADICIONALES TAL COMO UN INHIBIDOR DE CCR2/5 COMO CENICRIVIROC EN UNA DOSIS DE 50 MG A 250 MG. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO O LA PREVENCION DEL TRASTORNO HEPATICO CRONICO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394446P | 2016-09-14 | 2016-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190972A1 true PE20190972A1 (es) | 2019-07-09 |
Family
ID=60043251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000497A PE20190972A1 (es) | 2016-09-14 | 2017-09-12 | Combinacion de agonistas de fxr |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210290610A1 (es) |
| EP (1) | EP3512558A1 (es) |
| JP (1) | JP6878596B2 (es) |
| KR (1) | KR102218498B1 (es) |
| CN (1) | CN109689105A (es) |
| AR (1) | AR109652A1 (es) |
| AU (2) | AU2017328999B2 (es) |
| BR (1) | BR112019004684A2 (es) |
| CA (1) | CA3036760A1 (es) |
| CL (1) | CL2019000625A1 (es) |
| CO (1) | CO2019002245A2 (es) |
| CR (1) | CR20190125A (es) |
| EC (1) | ECSP19016844A (es) |
| IL (1) | IL264628A (es) |
| JO (1) | JOP20190040A1 (es) |
| MX (1) | MX2019003021A (es) |
| PE (1) | PE20190972A1 (es) |
| PH (1) | PH12019500326A1 (es) |
| RU (1) | RU2019110780A (es) |
| SG (1) | SG11201900651PA (es) |
| TW (1) | TW201811372A (es) |
| WO (1) | WO2018051230A1 (es) |
| ZA (1) | ZA201900528B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3585384A1 (en) * | 2017-02-24 | 2020-01-01 | Genfit | Pharmaceutical compositions for combination therapy |
| JP2021525750A (ja) * | 2018-05-31 | 2021-09-27 | ノバルティス アーゲー | トロピフェクサーとセニクリビロックとを含む組合せ |
| CN114025760B (zh) * | 2019-07-18 | 2023-12-01 | 埃尼奥制药公司 | 改进的用eyp001的治疗 |
| AU2020405182B2 (en) * | 2019-12-20 | 2024-03-14 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| CN112402430A (zh) * | 2020-12-11 | 2021-02-26 | 大连医科大学 | 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6987121B2 (en) * | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
| RS52810B8 (sr) * | 2008-11-26 | 2019-08-30 | Pfizer | 3-aminociklopentankarboksamidi kao modulatori hemokinskih receptora |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| CU24375B1 (es) * | 2013-11-05 | 2018-12-05 | Novartis Ag | Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x |
| WO2015138986A1 (en) * | 2014-03-13 | 2015-09-17 | Salk Institute For Biological Studies | Fxr agonists and methods for making and using |
| AU2015314830B2 (en) * | 2014-09-12 | 2021-01-07 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| JP2017537960A (ja) * | 2014-12-18 | 2017-12-21 | ノバルティス アーゲー | 肝疾患および胃腸疾患の治療に使用するためのｆｘｒアゴニストとしてのアザビシクロオクタン誘導体 |
| US11110083B2 (en) * | 2016-02-22 | 2021-09-07 | Novartis Ag | Methods for treating liver disorders using FXR agonists |
-
2017
- 2017-06-16 JO JOP/2019/0040A patent/JOP20190040A1/ar unknown
- 2017-09-12 CA CA3036760A patent/CA3036760A1/en not_active Abandoned
- 2017-09-12 CN CN201780056097.XA patent/CN109689105A/zh active Pending
- 2017-09-12 BR BR112019004684A patent/BR112019004684A2/pt not_active IP Right Cessation
- 2017-09-12 KR KR1020197009426A patent/KR102218498B1/ko active IP Right Grant
- 2017-09-12 MX MX2019003021A patent/MX2019003021A/es unknown
- 2017-09-12 RU RU2019110780A patent/RU2019110780A/ru not_active Application Discontinuation
- 2017-09-12 EP EP17781186.6A patent/EP3512558A1/en not_active Withdrawn
- 2017-09-12 US US16/332,446 patent/US20210290610A1/en not_active Abandoned
- 2017-09-12 AU AU2017328999A patent/AU2017328999B2/en not_active Ceased
- 2017-09-12 PE PE2019000497A patent/PE20190972A1/es unknown
- 2017-09-12 WO PCT/IB2017/055503 patent/WO2018051230A1/en unknown
- 2017-09-12 SG SG11201900651PA patent/SG11201900651PA/en unknown
- 2017-09-12 CR CR20190125A patent/CR20190125A/es unknown
- 2017-09-12 JP JP2019535998A patent/JP6878596B2/ja active Active
- 2017-09-14 AR ARP170102541A patent/AR109652A1/es unknown
- 2017-09-14 TW TW106131530A patent/TW201811372A/zh unknown
-
2019
- 2019-01-25 ZA ZA2019/00528A patent/ZA201900528B/en unknown
- 2019-02-03 IL IL264628A patent/IL264628A/en unknown
- 2019-02-15 PH PH12019500326A patent/PH12019500326A1/en unknown
- 2019-03-11 EC ECSENADI201916844A patent/ECSP19016844A/es unknown
- 2019-03-12 CL CL2019000625A patent/CL2019000625A1/es unknown
- 2019-04-15 CO CONC2019/0002245A patent/CO2019002245A2/es unknown
-
2020
- 2020-03-19 AU AU2020201980A patent/AU2020201980A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019500326A1 (en) | 2019-11-11 |
| WO2018051230A1 (en) | 2018-03-22 |
| JP6878596B2 (ja) | 2021-05-26 |
| AU2017328999A1 (en) | 2019-02-21 |
| AU2020201980A1 (en) | 2020-04-09 |
| AR109652A1 (es) | 2019-01-09 |
| CN109689105A (zh) | 2019-04-26 |
| JP2019526644A (ja) | 2019-09-19 |
| KR102218498B1 (ko) | 2021-02-22 |
| IL264628A (en) | 2019-02-28 |
| SG11201900651PA (en) | 2019-04-29 |
| BR112019004684A2 (pt) | 2019-05-28 |
| CL2019000625A1 (es) | 2019-05-17 |
| MX2019003021A (es) | 2019-09-26 |
| JOP20190040A1 (ar) | 2019-03-10 |
| AU2017328999B2 (en) | 2019-12-19 |
| KR20190044666A (ko) | 2019-04-30 |
| RU2019110780A3 (es) | 2020-11-30 |
| ECSP19016844A (es) | 2019-03-29 |
| ZA201900528B (en) | 2021-06-30 |
| CA3036760A1 (en) | 2018-03-22 |
| RU2019110780A (ru) | 2020-10-15 |
| TW201811372A (zh) | 2018-04-01 |
| CR20190125A (es) | 2019-06-04 |
| US20210290610A1 (en) | 2021-09-23 |
| EP3512558A1 (en) | 2019-07-24 |
| CO2019002245A2 (es) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190972A1 (es) | Combinacion de agonistas de fxr | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| PE20141822A1 (es) | Inhibidor de la quinasa reguladora de la senal de apoptosis | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| PE20161218A1 (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| CO2017002714A2 (es) | Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo | |
| CL2017001362A1 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| CL2017000609A1 (es) | Terapia de combinación con cenicriviroc para el tratamiento de la fibrosis | |
| EA201691320A1 (ru) | Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов | |
| CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
| DOP2018000196A (es) | Metodos para tratar la depresion con antagonistas del receptor de orexina-2 | |
| BR112018011154A2 (pt) | dispersões sólidas compreendendo um estimulador de sgc | |
| EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
| CL2021000044A1 (es) | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017) | |
| CL2017001479A1 (es) | Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| CL2016002497A1 (es) | “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct | |
| MA39443A1 (fr) | Nouvelle formulation de méloxicam | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| UY36574A (es) | Inhibidores de bromodominios | |
| SV2016005313A (es) | Derivados de carboxamida | |
| AR104342A1 (es) | Compuesto heterocíclico | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |